Login to Your Account

Spinifex's Neuropathic Pain Drug Proves Mettle in Phase II

By Nuala Moran
Staff Writer

Wednesday, August 29, 2012
LONDON – Spinifex Pharmaceuticals announced positive Phase II results of EMA401 in controlling neuropathic pain following herpes zoster (shingles) infection, and the company is now weighing the commercialization strategy for the product.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription